Walgreens Health Services > Specialty Pharmacy > Drug pipeline report
Drug pipeline report
PrintThe Walgreens Specialty Pharmacy Pipeline Report focuses on medications that are newly approved -- or soon to be approved by the FDA -- and could have a significant impact on treatment, its costs and/or insurance coverage for certain health conditions.
The report is updated quarterly, so please check here for the most recent pipeline developments.
First Quarter 2010
Medications to watch: Egrifta (tesamorelin), Ridaforolimus, Dimebon (latrepirdine) and Huntexil® (pridopidine)
Fourth Quarter 2009
Medications to watch: Votrient™(pazopanib), Replagal® (agalsidase alfa) and Tafamidis
Third Quarter 2009
Medications to watch: Omacetaxine, Velaglucerase alfa and Benlysta™ (belimumab)
Second Quarter 2009
Medications to watch: Trabectedin, Pirfenidone, Boceprevir and Telaprevir
First Quarter 2009
Medications to watch: Pegloticase, Fampridine-SR, Fingolimod, Mylinax®(oral cladribine), Arzerra™ (ofatumumab)
Fourth Quarter 2008
Medications to watch: Afinitor® (everolimus, RAD001), Denosumab, Dirucotide (MBP8298)
Third Quarter 2008
Medications to watch: Berinet® P and Cinryze™ (C1 inhibitor), Viveta, Corifollitropin alfa
Second Quarter 2008
Report updated 7/16/2008. Medications to watch: Cimzia® Bosatria®, Zactima®
First Quarter 2008
Medications to watch: Nplate™ and Promacta™, Numax®, Albuferon®
Fourth Quarter 2007
Medications to watch: Nexavar®, Golimumab, Ustekinumab, Lestaurtinib
Third Quarter 2007
Medications to watch: Ixabepilone, Kuvan™ (sapropterin), Oral Hycamtin® (topotecan)
Second Quarter 2007
Medications to watch: Soliris™, Thelin™, Satraplatin
First Quarter 2007
Medications to watch: Torisel™, Tasigna®, Somatuline®, Autogel®, Actemra™
Fourth Quarter 2006
Medications to watch: Elaprase™, Tykerb®, Fingolimod, Alfimeprase